Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 6Active not recruiting 5Completed 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 390Neoplasms 382Lung Neoplasms 266Multiple Myeloma 246Colorectal Neoplasms 235Neoplasm Metastasis 217Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 166Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 141Carcinoma, Renal Cell 141Lymphoma 137Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 124Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 119Head and Neck Neoplasms 115Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 100Lymphoma, Follicular 96Sarcoma 95

Interventions

Taxes 2Losartan 2Gemcitabine 2Albumin-Bound Paclitaxel 2durvalumab 1dehydroftorafur 1X-Rays 1Specimen Handling 1Radiotherapy 1Radiation 1Oxaliplatin 1Metformin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Adenocarcinoma × 1 year × Clear all
NCT05973331 2026-04-22

Prospective Validation of an EHR-based Pancreatic Cancer Risk Model

Beth Israel Deaconess Medical Center

Active not recruiting
6,134,060 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03245541 2025-10-07

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡